Noribogaine — the molecule your liver produces when it metabolizes ibogaine — is widely considered responsible for ibogaine's prolonged therapeutic window. While ibogaine itself clears the bloodstream within hours, noribogaine persists for days to weeks, continuing to act on receptors linked to mood regulation, opioid withdrawal, and neuroplasticity. Understanding this metabolite is central to understanding why a single ibogaine session can produce effects that last months.

What exactly is noribogaine and how is it formed?

Ibogaine is rapidly converted in the liver by the cytochrome P450 enzyme CYP2D6 through a process called O-demethylation, producing 12-hydroxyibogamine — the compound clinically known as noribogaine. This conversion begins within the first hour after ibogaine ingestion and accelerates as ibogaine concentrations peak.

Because CYP2D6 activity varies significantly between individuals — so-called poor metabolizers versus ultra-rapid metabolizers — the ratio of ibogaine to noribogaine in the bloodstream is not uniform. Research published in the Journal of Psychopharmacology by Mash and colleagues found that CYP2D6 genotype substantially influenced noribogaine plasma levels among opioid-dependent subjects, which may partly explain the wide variation in therapeutic outcomes and duration of effect that clinicians observe.

How long does noribogaine stay active in the body?

This is where noribogaine diverges sharply from its parent compound. Ibogaine has a plasma half-life of roughly 4–7 hours, while noribogaine's half-life ranges from approximately 28 to 49 hours in healthy volunteers, based on Phase I ascending-dose data published by Glue and colleagues in the Journal of Clinical Pharmacology (2016). In people with slower metabolic clearance, meaningful plasma concentrations can persist for several weeks.

That extended half-life has direct clinical implications. The acute psychoactive phase of ibogaine — the visionary, oneirogenic experience — correlates primarily with ibogaine itself. The quieter, post-acute period that follows, often described by patients as a sustained "reset," maps more closely onto noribogaine's pharmacokinetic curve. Clinicians working in legal treatment settings outside the US frequently note that patients report the most durable mood and craving changes during the window when noribogaine is still measurably present.

Which receptors does noribogaine act on?

Noribogaine has a distinct — though overlapping — receptor profile compared to ibogaine. Key targets identified in peer-reviewed literature include:

  • Serotonin transporter (SERT): Noribogaine is a potent serotonin reuptake inhibitor, with SERT affinity that rivals or exceeds that of several approved antidepressants. Baumann and colleagues at the National Institute on Drug Abuse demonstrated this in their foundational 2001 work in the Annals of the New York Academy of Sciences. This SERT activity is widely hypothesized to underlie the post-treatment antidepressant and anti-anxiety effects patients report.
  • Opioid receptors (κ and μ): Noribogaine acts as a weak partial agonist at kappa-opioid receptors and shows affinity at mu-opioid receptors. This interaction may buffer opioid withdrawal symptoms during the acute treatment phase and reduce cravings afterward.
  • NMDA receptor antagonism: Like ibogaine, noribogaine blocks NMDA glutamate receptors, a mechanism shared with ketamine and implicated in rapid antidepressant action and synaptic plasticity.
  • Sigma-2 receptors: Noribogaine shows higher sigma-2 receptor affinity than ibogaine, a target currently under investigation for roles in neuroinflammation and cellular stress response.

This multi-receptor pharmacology makes noribogaine difficult to categorize. It is not simply a metabolic byproduct — it is a pharmacologically active compound in its own right, working through mechanisms that are largely distinct from ibogaine's acute psychedelic action.

What does noribogaine contribute to anti-addiction outcomes?

Mash and colleagues' 2018 study in Frontiers in Pharmacology, drawing on data from an open-label observational cohort treated in Panama, reported that higher post-treatment noribogaine plasma levels were associated with greater reductions in opioid and cocaine cravings at one-month follow-up. While that study lacked a placebo control, the pharmacokinetic correlation is a meaningful signal.

Preclinical work has also shown that noribogaine independently reduces morphine self-administration in animal models, suggesting the metabolite carries genuine anti-addiction properties that do not require the full ibogaine experience to activate. Popik and Skolnick's thorough review in The Alkaloids (Academic Press, 1999) remains a key reference for this preclinical foundation.

This has prompted researchers to ask whether noribogaine could be developed as a standalone therapy — one that might preserve the therapeutic benefit while reducing the cardiac risks and acute psychological intensity associated with ibogaine itself. Glue's Phase I trial specifically evaluated standalone noribogaine dosing for this reason.

Safety note: Noribogaine, like ibogaine, carries QTc-prolonging effects on cardiac rhythm. Glue's 2016 trial documented dose-dependent QT interval prolongation with standalone noribogaine. Any treatment context involving ibogaine or its metabolites requires cardiac screening, ECG monitoring, and medically supervised administration. Deaths have been reported in association with ibogaine treatment, most frequently linked to cardiac arrhythmia. This risk profile applies to noribogaine as well and is a central reason ibogaine remains under active FDA regulatory scrutiny.

Is noribogaine being studied as a standalone drug?

Yes. Recognizing noribogaine's extended half-life, its non-hallucinogenic profile at lower doses, and its mechanistic overlap with effective antidepressants, several research groups have pursued it independently. DemeRx, a biopharmaceutical company, held an active IND with the FDA for noribogaine as a treatment for opioid use disorder — a program that marked one of the earliest formal regulatory engagements around ibogaine-class compounds in the US.

More recently, the broader ibogaine research landscape — including the landmark Stanford trial published in Nature Medicine examining ibogaine with magnesium in veterans with traumatic brain injury and PTSD — has renewed interest in understanding exactly which phase of the pharmacokinetic curve drives which therapeutic effect. Parsing ibogaine's acute action from noribogaine's sustained action is now a recognized priority in trial design.

What are the open scientific questions?

Despite substantial mechanistic work, several critical questions remain unresolved:

  1. Does SERT inhibition fully explain the antidepressant effect? Noribogaine's SERT potency is well-established, but conventional SSRIs require weeks of use to produce clinical benefit. Noribogaine's effects appear faster, suggesting neuroplasticity mechanisms — possibly via BDNF upregulation — may be equally important.
  2. How does CYP2D6 genotype affect treatment outcomes? Poor metabolizers produce less noribogaine from the same ibogaine dose, potentially limiting long-term benefit. Whether pre-treatment genotyping should guide dosing is unresolved.
  3. Can the cardiac risk be separated from the therapeutic benefit? QT prolongation appears to be a class effect of both compounds. Identifying structural analogs that retain receptor activity without hERG potassium channel blockade is an active area of medicinal chemistry research.
  4. What is the role of noribogaine in neuroplasticity? Animal studies suggest ibogaine-class compounds increase BDNF and promote synaptogenesis. Whether noribogaine specifically — rather than ibogaine — drives these changes in humans is not yet established in controlled trials.

Frequently Asked Questions

At the doses present during ibogaine metabolism, noribogaine is considered minimally or non-psychedelic. Glue's Phase I trial found that participants given standalone noribogaine did not report the intense visionary experiences associated with ibogaine. At higher doses, mild perceptual effects were noted, but the compound lacks ibogaine's potent kappa-opioid and 5-HT2A activity that drives the acute psychedelic state.
CYP2D6 genetic variation is one likely contributor. Poor metabolizers — estimated at 6–10% of people of European descent — convert ibogaine to noribogaine more slowly, potentially producing lower noribogaine exposure and shorter therapeutic duration. Other factors include baseline neurobiological state, the nature of the substance use disorder, concurrent medications that inhibit CYP2D6, and psychological readiness for the experience.
Yes. Noribogaine independently prolongs the QTc interval in a dose-dependent manner, as documented in Glue's 2016 Phase I trial. This means the cardiac risk window during an ibogaine treatment extends beyond when ibogaine itself is present. Individuals undergoing treatment require cardiac monitoring that accounts for noribogaine's longer half-life, not just the acute ibogaine phase.
Noribogaine is not approved by the FDA and is not legally available as a supplement or over-the-counter product in the US. Ibogaine itself is Schedule I. While noribogaine is a distinct chemical compound and its specific scheduling status is more nuanced, obtaining or using it outside of an approved clinical trial would carry significant legal and safety risks. Consult a legal and medical professional before pursuing any such inquiry.
Noribogaine's SERT affinity is pharmacologically comparable to approved SSRIs, but the comparison is not straightforward. SSRIs are taken daily and require weeks to produce antidepressant effects. Noribogaine is transiently present after a single ibogaine dose. The hypothesis is that noribogaine's multi-receptor action — combining SERT inhibition with NMDA antagonism and possible neuroplasticity promotion — produces a faster and more durable antidepressant effect, but head-to-head clinical trials do not yet exist.
Ibogaine is a Schedule I controlled substance under the US Controlled Substances Act, meaning it is federally illegal to manufacture, possess, or distribute outside of DEA-licensed research. It is not FDA-approved as a medicine. Legal ibogaine treatment is available in several other countries, including Mexico, Canada, and various European nations. As of 2026, the FDA has granted Breakthrough Therapy Designation to at least one ibogaine-related development program, signaling regulatory engagement, but no approved therapeutic exists in the US.
Based on Mash and colleagues' pharmacokinetic data and Glue's Phase I work, noribogaine is detectable in plasma for several days after treatment and may persist at low but measurable levels for two to four weeks depending on the dose administered and the individual's metabolic rate. Urine drug screens used in clinical settings may detect ibogaine-class compounds for a similar window, though standard panels do not routinely test for noribogaine.

The science of noribogaine is still maturing, and many of the most clinically important questions — about dosing, genotype-guided treatment, and long-term neurobiological effects — are active areas of ongoing research. If you are considering ibogaine treatment, speaking with a physician experienced in psychedelic medicine, and consulting with legal counsel familiar with the regulations in your jurisdiction, are essential first steps. The landscape is evolving quickly, and guidance from qualified professionals remains the most reliable path to making an informed decision.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.